UK markets open in 3 hours 45 minutes
NIKKEI 225
28,520.35 -284.50 (-0.99%) HANG SENG
26,157.68 +30.75 (+0.12%) CRUDE OIL
84.61 +0.85 (+1.01%) GOLD FUTURES
1,796.00 -0.30 (-0.02%) DOW
35,677.02 +73.92 (+0.21%) BTC-GBP
45,036.59 +331.16 (+0.74%)
Beam Therapeutics Inc. (BEAM)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
93.74-1.23 (-1.30%)
At close: 4:00PM EDT
93.95 +0.21 (+0.22%)
After hours: 05:58PM EDT
After hours: 05:58PM EDT
| Previous close | 94.97 |
| Open | 94.24 |
| Bid | 90.51 x 900 |
| Ask | 97.50 x 1100 |
| Day's range | 91.51 - 95.91 |
| 52-week range | 32.97 - 138.52 |
| Volume | 283,917 |
| Avg. volume | 638,212 |
| Market cap | 6.22B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.11 |
| Earnings date | 08 Nov 2021 - 12 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 127.13 |
- Motley Fool
2 Gene-Editing Stocks to Have on Your Radar Right Now
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
- Motley Fool
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
After the Food and Drug Administration paused Allogene Therapeutics' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. The FDA's intervention appeared to spur trading by ARK Invest in Beam Therapeutics (NASDAQ: BEAM), Intellia Therapeutics (NASDAQ: NTLA), and Schrödinger (NASDAQ: SDGR).
- Zacks
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
© 2021 Verizon Media. All rights reserved.
